PMS-PIROXICAM SUPPOSITORIES -20MG SUPPOSITORY

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

PIROXICAM

Dostupno od:

PHARMASCIENCE INC

ATC koda:

M01AC01

INN (International ime):

PIROXICAM

Doziranje:

20MG

Farmaceutski oblik:

SUPPOSITORY

Sastav:

PIROXICAM 20MG

Administracija rute:

RECTAL

Jedinice u paketu:

30 SUPPOSITORIES

Tip recepta:

Prescription

Područje terapije:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0114612001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2016-10-28

Svojstava lijeka

PRODUCT MONOGRAPH
Pr
pms-PIROXICAM
Piroxicam, USP
10 mg and 20 mg Capsules
10 mg and 20 mg Suppositories
Nonsteroidal Anti-Inflammatory Drug (NSAID)
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue
February 17, 2010
Montreal, Quebec
H4P 2T4
CONTROL # 131400
_ _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
.................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL
PHARMACOLOGY.............................................................23
STORAGE AND
STABILITY..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL
INFORMATION..........................................................................26
CLINICAL TRIALS
..........................................................................................................27
DETAILED PHARMACOLOGY
.....................................................................................27